同和药业(300636) - 2018 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 65.52% to CNY 6,496,829.17 for the current period[7] - Operating revenue decreased by 11.26% to CNY 61,575,807.45 for the current period[7] - Basic earnings per share decreased by 74.14% to CNY 0.0812[7] - Total operating revenue for the current period was CNY 187,395,780.57, a decrease from CNY 222,373,919.19 in the previous period, representing a decline of approximately 16%[45] - Net profit for the current period was CNY 26,217,158.27, down from CNY 52,962,102.03 in the previous period, indicating a decrease of approximately 50%[46] - The total profit for the current period was CNY 28,453,348.38, down from CNY 61,503,411.85, a decrease of about 54%[46] - The total comprehensive income for the current period was CNY 26,217,158.27, down from CNY 52,962,102.03, indicating a decline of about 50%[47] - The net profit for the third quarter was CNY 25,773,031.05, a decrease of 50.3% compared to CNY 51,859,381.30 in the same period last year[50] - Operating profit for the quarter was CNY 27,760,170.09, down from CNY 53,413,601.71 year-over-year, reflecting a decline of 48.0%[50] Assets and Liabilities - Total assets increased by 10.87% to CNY 800,820,823.38 compared to the end of the previous year[7] - Net assets attributable to shareholders increased by 3.99% to CNY 662,515,612.56 compared to the end of the previous year[7] - The total liabilities increased significantly, with accounts payable and notes payable rising by 168.20% to ¥79,121,824.65, reflecting increased obligations for completed equipment projects[18] - The total liabilities increased to CNY 136,329,175.07 from CNY 83,754,385.03, an increase of 62.9%[35] - The company's equity attributable to shareholders increased from RMB 637,101,061.23 to RMB 662,515,612.56, showing a growth of about 4%[31] Cash Flow - Cash flow from operating activities increased by 147.55% to CNY 58,813,299.97 year-to-date[7] - The company reported a 107.14% decrease in net cash flow from financing activities to -¥18,734,235.00, due to no new investments and dividend payments during the period[20] - Cash flow from operating activities generated a net amount of CNY 58,813,299.97, significantly up from CNY 23,758,208.31 in the previous year, representing a growth of 147.0%[51] - The cash flow from financing activities resulted in a net outflow of CNY 18,734,235.00, contrasting with a net inflow of CNY 262,435,850.66 in the same period last year[57] Income and Expenses - Total operating costs increased to CNY 57,577,540.38, up from CNY 54,561,796.99, reflecting a rise of 5.5%[36] - Research and development expenses increased by 69.63% to ¥15,806,396.43, driven by new R&D projects and increased personnel costs[19] - Research and development expenses rose significantly to CNY 6,478,512.91, compared to CNY 3,362,347.42, marking an increase of 92.5%[36] - The company reported a tax expense of CNY 2,236,190.11, compared to CNY 8,541,309.82 in the previous period, a decrease of approximately 74%[46] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,387[11] - The largest shareholder, Pang Zhengwei, holds 19.09% of the shares, with 15,536,881 shares[11] - The company did not conduct any repurchase transactions among the top ten shareholders during the reporting period[12] Other Income - Non-recurring gains and losses totaled CNY 11,568,903.46, primarily from government subsidies and investment income[8] - Other income increased by 188.06% to ¥8,029,537.06, primarily due to a rise in government subsidies related to daily activities[19] - Investment income surged by 576.49% to ¥5,687,060.10, resulting from increased returns on idle funds and investment products[19] Inventory and Receivables - Accounts receivable decreased by 30.72% to ¥26,048,210.53, primarily due to a reduction in customer receivables[18] - Inventory increased from RMB 138,075,482.95 to RMB 169,842,940.51, reflecting a growth of about 22.9%[29] - The company's cash and cash equivalents decreased from RMB 23,936,687.79 to RMB 21,220,700.77 during the reporting period[29] Compliance and Governance - The company reported no overdue commitments from major shareholders or related parties during the reporting period[23] - There were no violations regarding external guarantees during the reporting period[24] - The company did not execute any cash dividend policy during the reporting period[24]